Du är här


Actelion Pharmaceuticals Ltd: Actelion's Chief Scientific Officer Martine Clozel awarded the Tomoh Masaki award by the 14th International Conferences on Endoth

Actelion Pharmaceuticals Ltd / Actelion's Chief Scientific Officer Martine
Clozel awarded the Tomoh Masakiaward by the 14th International Conferences on
Endothelin . Processed and transmitted by NASDAQ OMX Corporate Solutions.The
issuer is solely responsible for the content of this announcement.
2015 -
Actelion Ltd (SIX: ATLN) today announced that its Chief Scientific Officer and
Member of the Actelion Founding team, Martine Clozel, has been awarded the
Tomoh Masaki Award by the International Conferences on Endothelin, the
bi-annual scientific event, currently taking place for the 14th time in
Savannah, Georgia/USA.

In its tribute, the award committee highlighted Dr. Clozel's contribution to
successfully discovering multiple endothelin receptor antagonists, especially
Tracleer®(bosentan) and Opsumit®(macitentan), two molecules that each made
history in the field of pulmonary arterial hypertension.

Accepting the award, Dr. Clozel highlighted her long-term commitment to turn
groundbreaking scientific achievements, such as the discovery of the
endothelin system by Professor Tomoh Masaki and his team, into innovative
medicines that change the lives of patients. She also highlighted the key
contribution of Professor Masashi Yanagisawa, who was the lead author on the
study in the discovery of endothelin and was the first recipient of the
award, as well as Professor Kastutoshi Goto, the second recipient, for his
role in understanding the pathophysiology of endothelin.

Dr. Clozel said: "It is my privilege to be part of such a vibrant research
community as the one that covers endothelin science. I have been actively
participating to every international conference on endothelin since the very
first one in 1988 in London. At every meeting, new information has been
presented that showed the path forward for new endothelin-based medical

Dr. Clozel specifically highlighted the ongoing further research and
development efforts at Actelion in the field of endothelin receptor
antagonists, with multiple clinical studies either ongoing or in the process
of being initiated, to identify further applications where counteracting the
deleterious effects of an endothelin overproduction could result in
significant changes in clinical outcome and patient well-being.




Professor Tomoh Masaki, a Japanese physician-scientist born in 1934, is
particularly known for the discovery of endothelium-derived peptide
endothelin and its receptors, among many other scientific achievements. The
Tomoh Masaki Award was established in 2011 by the Endothelin International
Advisory Board of The International Conferences on Endothelin as a biannual
scientific prize with the purpose of "recognizing individuals for their
outstanding scientific achievements to advance science and medicine, the
ability to motivate and mentor others, and for continuous scientific
excellence in the endothelin field".

The International Advisory Board on Endothelin Conferences is a group of
leading academic scientists from around the world who preside over the
organization of these conferences and is responsible for selecting Tomoh
Masaki award recipients. These bi-annual conferences that first began nearly
25 years ago rotate between Europe, North America and Japan and represent a
unique partnership of a diverse range of scientists from both industry and
academia. These meetings are typically hosted by one of the host country's
scientific societies, which this year is the American Physiological Society,
founded in 1887 and is the oldest biomedical research organization in the
North America.


Martine Clozel, a pediatrician specialized in neonatal intensive care, has an
MD degree from Nancy University, France, and received further training in
physiology and pharmacology from McGill University, Montreal, and the
University of California, San Francisco.

During her 11 years at F. Hoffmann-La Roche Ltd, she initiated the research
project on endothelin and endothelin receptor antagonists which led to the
discovery and clinical development of bosentan (Tracleer®), tezosentan,
clazosentan and other molecules. In 1997 she was awarded the Hoffmann-La
Roche Research Prize for her achievements in the field of endothelin

In 1997 Martine co-founded Actelion Pharmaceuticals Ltd, where she is Senior
Vice President, Head of Drug Discovery, Pharmacology&Preclinical Development.
Under her leadership, Actelion applied a tailored drug discovery effort that
resulted in Opsumit (macitentan), a novel endothelin receptor antagonist
currently available in more than 30 markets worldwide.

Dr. Clozel is the author on more than 90 scientific publications in the field
of endothelin science, in particular the seminal publication published in
Nature (21 October 1993) titled "The pathophysiological role of endothelin
revealed by the first orally active endothelin receptor antagonist".

Martine also serves as the Chief Scientific Officer and a member of the
Extended Actelion Executive Committee.


The endothelium is an organ consisting of a single layer of cells between the
blood stream and the blood vessel wall. The main functions of the endothelium

* maintenance of blood vessel tone, which is critical for regulating blood
pressure levels
* prevention of blood clots forming on the vessel wall by providing a
non-adhesive surface

Endothelial cells produce several vasoactive chemical factors, among them
endothelin and nitric oxide, which work in opposition. Nitric oxide dilates
blood vessels, prevents platelet adhesion, and inhibits cell proliferation.

Endothelin, however, is a powerful blood vessel constrictor that also promotes
cell proliferation. In a normal healthy state, the body maintains a balance
between nitric oxide and endothelin. In contrast, in certain disease states
endothelin is produced in excess. In addition to causing vasoconstriction,
the narrowing of blood vessels, excessive endothelin can:

* stiffen blood vessels and tissues by promoting fibrosis, the accumulation
of connective tissue
* cause vascular remodeling (a change in the vessels' structure), vascular
hypertrophy (an increase in the thickness of blood vessel walls), and
cardiac hypertrophy
* predispose the vessels to inflammation


Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder
characterized by abnormally high blood pressure in the arteries between the
heart and lungs of an affected individual. The symptoms of PAH are
non-specific and can range from mild breathlessness and fatigue during normal
daily activity to symptoms of right heart failure and severe restrictions on
exercise capacity and ultimately reduced life expectancy.

PAH is one group within the classification of pulmonary hypertension (PH).
This group includes idiopathic PAH, heritable PAH and PAH caused by factors
which include connective tissue disease, HIV infection and congenital heart

The last decade has seen significant advances in the understanding of the
pathophysiology of PAH, which has been paralleled with developments of
treatment guidelines and new therapies. Drugs targeting the three pathways
that have been established in the pathogenesis of PAH are endothelin receptor
antagonists (ERAs), prostacyclins and phosphodiesterase-5 inhibitors. PAH
treatments have transformed the prognosis for PAH patients from symptomatic
improvements in exercise tolerance 10 years ago to delayed disease
progression today. Improved disease awareness and evidence-based guidelines
developed from randomized controlled clinical trial data have highlighted the
need for early intervention, goal-oriented treatment and combination therapy.

In PAH, survival rates are unacceptably low and PAH remains incurable.


Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,
development and commercialization of innovative drugs for diseases with
significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH).
Our portfolio of PAH treatments covers the spectrum of disease, from WHO
Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous
medications. Although not available in all countries, Actelion has treatments
approved by health authorities for a number of specialist diseases including
Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in
patients suffering from systemic sclerosis, and mycosis fungoides type
cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all
key markets around the world including Europe, the US, Japan, China, Russia
and Mexico, Actelion has its corporate headquarters in Allschwil / Basel,

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as
part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All
trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations&Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62

The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates", "believes", "expects",
"may", "are expected to", "will", "will continue", "should", "would be",
"seeks", "pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of
the company's investment and research and development programs and
anticipated expenditures in connection therewith, descriptions of new
products expected to be introduced by the company and anticipated customer
demand for such products and products in the company's existing portfolio.
Such statements reflect the current views of the company with respect to
future events and are subject to certain risks, uncertainties and
assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future
results, performances or achievements that may be expressed or implied by
such forward-looking statements. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those described herein as
anticipated, believed, estimated or expected.

Press Release PDF

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.